2025-09-09 - Analysis Report
Okay, here's an analysis of SDGR (Schrodinger Inc.) based on the data you provided.

**Report: SDGR (Schrodinger Inc.) Analysis**

Schrodinger Inc. is a company focused on developing software for drug discovery and materials science.

**1. Performance Metrics vs. S&P 500 (VOO)**

*   **Cumulative Return (SDGR):** -54.65%
*   **Cumulative Return (VOO):** 55.47%
*   **Absolute Divergence (SDGR - VOO):** -112.1%
*   **Relative Divergence:** 0.5

**Analysis:**  SDGR has significantly underperformed the S&P 500 (VOO) over the period considered.  The divergence is currently at -112.1%, indicating a substantial negative difference in cumulative returns. The relative divergence of 0.5 suggests that the underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
| ---------- | ------ | ----- | ------ | ----- | ------ |
| 2020-2022  | -74.0% | 68.9% | -88.0% | -0.1 | 1.4    |
| 2021-2023  | -65.0% | 68.9% | -82.0% | -0.0 | 2.7    |
| 2022-2024  | 8.0%   | 72.4% | -16.0% | -0.0 | 1.4    |
| 2023-2025  | -1.0%  | 74.0% | -53.0% | -0.0 | 1.4    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows highly volatile returns, with significant negative performance in earlier periods, improving more recently.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating substantial risk.
*   **Alpha:** The negative alpha values suggest underperformance relative to the benchmark (S&P 500), indicating the investment's return is not compensating well for the risk taken.
*   **Beta:** The beta values close to zero indicate that SDGR's price movements are largely uncorrelated with the S&P 500, which could mean its performance is driven by company-specific factors rather than broader market trends.
*   **Cap(B):** Market capitalization is roughly stable over recent periods.

**2. Recent Price Action**

*   **Current Price:** $19.13
*   **Last-market:** {'price': 19.44, 'previousClose': 19.13, 'change': 1.62}
*   **5-day Moving Average:** 19.20
*   **20-day Moving Average:** 19.44
*   **60-day Moving Average:** 20.61

**Analysis:** The stock is trading below its 20-day and 60-day moving averages, suggesting a short-term downward trend. However, the Last-market data indicates a significant change, suggesting a 1.62 rise compared to the previous close.

**3. Technical Indicators and Forward-Looking Estimates**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 47.39 (Neutral)
*   **PPO:** 0.048 (Positive)
*   **Hybrid Signal:** Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Delta Previous Relative Divergence (20-day):** 0.5 (+), indicating short-term upward momentum.
*   **Expected Return (%):** -5808.5% (Highly Negative)

**Analysis:**

*   The MRI suggests a low-risk environment, which might seem contradictory given the other metrics. However, MRI might be based on different factors or a different timeframe.
*   The RSI is neutral, not indicating overbought or oversold conditions.
*   The PPO being positive suggests that the shorter-term moving average is above the longer-term moving average, a potentially bullish signal.
*   The Hybrid Signal is cautiously recommending a buy.
*   The large negative Expected Return is very concerning, suggesting a highly unfavorable long-term outlook compared to the S&P 500. The significant change in Last-market price suggests volatility and could be due to recent news or events.

**4. Recent News & Significant Events**

*   **August 27, 2025:** Presentation at Morgan Stanley Global Healthcare Conference
*   **August 15, 2025:** Inducement Grants under Nasdaq Listing Rule
*   **August 14, 2025:** Discontinuation of SGR-2921 Program
*   **August 6, 2025:** Q2 Loss, Beats Revenue Estimates
*   **August 6, 2025:** Second Quarter 2025 Financial Results

**Analysis:**

*   The news is mixed. Presentation at a conference is generally positive, and beating revenue estimates is also good.
*   However, the discontinuation of the SGR-2921 program is a negative development, and the reported Q2 loss confirms the financial challenges.
*   Inducement grants can be seen as positive for attracting talent but also may dilute existing shareholders.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy
*   **Mean (1=StrongBuy~5=Sell):** 1.38 (Strong Buy)
*   **Opinions:** 9
*   **Target Price (avg/high/low):** 28.11 / 33.00 / 19.00

**Analysis:** Analyst opinions are overwhelmingly positive, with a Strong Buy consensus and a mean rating of 1.38. The average target price of $28.11 suggests a significant upside potential from the current price. However, recent rating changes are not available to assess the latest sentiment.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue |
| ---------- | ----- | ------- |
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2024-07-31 | -0.74 | 0.05 B$ |
| 2025-08-06 | -0.74 | 0.05 B$ |

**Analysis:** The company is consistently reporting losses (negative EPS). Revenue is relatively stable but not high enough to generate profits.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| ---------- | ------- | ------------- |
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |
| 2024-06-30 | $0.05B  | 66.20%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
| ---------- | ------- | -------- |
| 2025-06-30 | $0.34B  | -12.59%  |
| 2025-03-31 | $0.37B  | -16.01%  |
| 2024-12-31 | $0.42B  | -9.54%   |
| 2024-09-30 | $0.45B  | -8.49%   |
| 2024-06-30 | $0.47B  | -11.40%  |

**Analysis:** Revenue has fluctuated, and profit margins, while seemingly high, are not translating into overall profitability due to high operating costs. Equity is decreasing over time, and ROE is negative, indicating poor profitability relative to equity.

**7. Overall Summary**

Schrodinger (SDGR) presents a mixed picture.

*   **Negatives:** Significant underperformance compared to the S&P 500, high volatility, consistent losses, decreasing equity, and a highly negative expected return. Recent news includes the discontinuation of a program, which is a negative signal.
*   **Positives:** Strong Buy analyst consensus with a substantial upside target price, recent price uptick indicated by the last market close, high profit margins, and presentation at a major conference.
*   **Concerns:** Discrepancy between analyst optimism and the company's financial performance. The large negative expected return needs careful consideration. The discontinuation of the SGR-2921 program is a key concern.

**Conclusion:** Investing in SDGR appears to be high-risk. While analysts are optimistic and there are some positive technical indicators, the company's financial performance and the significant underperformance compared to the market warrant caution. A deeper dive into the reasons behind the negative expected return and the discontinued program is crucial before making any investment decisions.
